Literature DB >> 18792874

Complement activation and cardiovascular disease.

M Bjerre1, T K Hansen, A Flyvbjerg.   

Abstract

The mechanisms by which tissue injury after acute myocardial infarction occurs have not been fully elucidated, but considerable evidence suggests that activation of complement plays an important role in the pathophysiology. Reperfusion of the ischemic myocardium is strictly necessary to rescue the exposed tissue from eventual death. However, reversion of the blood supply is also associated with reperfusion injury contributing to tissue injury. Activation of the complement system has indisputable beneficial effects in the immune defense and in the clearance of damaged tissue and apoptotic cells, but excessive activation of the system may lead to uncontrolled tissue damage. This review focuses on the role of complement activation, with focus on the lectin pathway, endothelial dysfunction and cardiovascular diseases, including ischemic heart disease and diabetic angiopathy. Finally, potential therapeutic strategies targeting the complement system are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18792874     DOI: 10.1055/s-0028-1083786

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Complement Component C3 Promotes Cerebral Ischemia/Reperfusion Injury Mediated by TLR2/NFκB Activation in Diabetic Mice.

Authors:  Zheng Lin; Haoran Lin; Wenlu Li; Yuwen Huang; Haibin Dai
Journal:  Neurochem Res       Date:  2018-06-13       Impact factor: 3.996

2.  Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

Authors:  Linda G Mellbin; Mette Bjerre; Steffen Thiel; Troels K Hansen
Journal:  Diabetes Care       Date:  2012-02-22       Impact factor: 19.112

3.  Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort.

Authors:  Sara Meziani; Giulia Ferrannini; Mette Bjerre; Troels K Hansen; Viveca Ritsinger; Anna Norhammar; Viveca Gyberg; Per Näsman; Lars Rydén; Linda G Mellbin
Journal:  Cardiovasc Diabetol       Date:  2022-07-08       Impact factor: 8.949

4.  Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

Authors:  L G Mellbin; A Hamsten; K Malmberg; R Steffensen; L Rydén; J Ohrvik; T K Hansen
Journal:  Diabetes Care       Date:  2010-08-06       Impact factor: 17.152

5.  Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction.

Authors:  Anush V Karapetyan; Yuri M Klyachkin; Samy Selim; Manjula Sunkara; Khaled M Ziada; Donald A Cohen; Ewa K Zuba-Surma; Janina Ratajczak; Susan S Smyth; Mariusz Z Ratajczak; Andrew J Morris; Ahmed Abdel-Latif
Journal:  Stem Cells Dev       Date:  2013-02-19       Impact factor: 3.272

6.  Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease.

Authors:  Thaisa Lucas Sandri; Kárita Cláudia Freitas Lidani; Fabiana Antunes Andrade; Christian G Meyer; Peter G Kremsner; Iara J de Messias-Reason; Thirumalaisamy P Velavan
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

7.  Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Authors:  Elisabetta Valoti; Marina Noris; Annalisa Perna; Erica Rurali; Giulia Gherardi; Matteo Breno; Aneliya Parvanova Ilieva; Ilian Petrov Iliev; Antonio Bossi; Roberto Trevisan; Alessandro Roberto Dodesini; Silvia Ferrari; Nadia Stucchi; Ariela Benigni; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Front Genet       Date:  2019-07-26       Impact factor: 4.599

Review 8.  Large uremic toxins: an unsolved problem in end-stage kidney disease.

Authors:  Martin J Wolley; Colin A Hutchison
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.